News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
530,405 Results
Type
Article (10204)
Company Profile (177)
Press Release (519932)
Multimedia
Podcasts (5)
Webinars (7)
Section
Business (180258)
Career Advice (371)
Deals (27793)
Drug Delivery (9)
Drug Development (61501)
Employer Resources (27)
FDA (10458)
Job Trends (9423)
News (261396)
Policy (19880)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (2)
Academia (583)
Accelerated approval (29)
ADA (19)
Adcomms (2)
Allergies (118)
Alliances (36679)
ALS (136)
Alzheimer's disease (1087)
Antibody-drug conjugate (ADC) (365)
Approvals (11180)
Artificial intelligence (391)
ASCO (194)
Autoimmune disease (246)
Automation (33)
Bankruptcy (271)
Best Places to Work (7606)
BIO (44)
Biologics (2)
BIOSECURE Act (2)
Biosimilars (161)
BioSpace Insights (19)
Biotechnology (114)
Bladder cancer (155)
Brain cancer (40)
Breast cancer (538)
Cancer (4249)
Cardiovascular disease (257)
Career advice (307)
Career pathing (3)
CAR-T (222)
CDC (2)
Celiac Disease (1)
Cell therapy (572)
Cervical cancer (37)
Clinical research (56034)
Collaboration (1498)
Commercialization (3)
Compensation (1588)
Complete response letters (38)
COVID-19 (940)
CRISPR (65)
C-suite (919)
Cystic fibrosis (95)
Data (6594)
Denatured (4)
Depression (120)
Dermatology (71)
Diabetes (387)
Diagnostics (4323)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (6)
Drug discovery (195)
Drug pricing (17)
Drug shortages (2)
Duchenne muscular dystrophy (171)
Earnings (78268)
Editorial (4)
Employer branding (4)
Employer resources (25)
Events (96049)
Executive appointments (852)
FDA (13488)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (20)
Frontotemporal dementia (27)
Funding (1093)
Gene editing (132)
Generative AI (15)
Gene therapy (350)
GLP-1 (405)
Government (1139)
Grass and pollen (3)
Guidances (322)
Healthcare (9906)
Hematology (129)
HIV (54)
Huntington's disease (26)
IgA nephropathy (71)
Immunology and inflammation (129)
Immuno-oncology (71)
Indications (180)
Infectious disease (1155)
Inflammatory bowel disease (154)
Inflation Reduction Act (5)
Influenza (94)
Intellectual property (271)
Interviews (49)
IPO (13529)
IRA (5)
Job creations (2207)
Job search strategy (290)
JPM (3)
Kidney cancer (20)
Labor market (1)
Layoffs (90)
Leadership (2)
Legal (5393)
Licensing (9)
Liver cancer (51)
Longevity (18)
Lung cancer (634)
Lymphoma (315)
Machine learning (33)
Management (7)
Manufacturing (679)
Marketing (11)
MASH (165)
Medical device (8757)
Medtech (8903)
Mergers & acquisitions (15376)
Metabolic disorders (841)
mRNA (65)
Multiple sclerosis (135)
NASH (7)
Neurodegenerative disease (268)
Neuropsychiatric disorders (51)
Neuroscience (2145)
NextGen: Class of 2026 (3366)
Non-profit (958)
Now hiring (4)
Obesity (263)
Opinion (33)
Ovarian cancer (169)
Pain (191)
Pancreatic cancer (211)
Parkinson's disease (255)
Partnered (12)
Patents (514)
Patient recruitment (624)
Peanut (45)
People (45242)
Pharmaceutical (40)
Pharmacy benefit managers (8)
Phase 1 (17870)
Phase 2 (25064)
Phase 3 (17187)
Pipeline (8380)
Policy (33)
Postmarket research (1707)
Preclinical (7336)
Press Release (41)
Prostate cancer (222)
Psychedelics (9)
Radiopharmaceuticals (252)
Rare diseases (669)
Real estate (3499)
Recruiting (13)
Regulatory (16950)
Reports (23)
Research institute (693)
Resumes & cover letters (48)
Rett syndrome (41)
RNA editing (5)
RSV (50)
Schizophrenia (140)
Series A (186)
Series B (141)
Service/supplier (5)
Sickle cell disease (69)
Spinal muscular atrophy (95)
Sponsored (8)
Startups (2302)
State (1)
Stomach cancer (3)
Supply chain (56)
Tariffs (7)
The Weekly (1)
Vaccines (405)
Venture capital (24)
Weight loss (92)
Women's health (83)
Worklife (1)
Date
Today (30)
Last 7 days (263)
Last 30 days (1848)
Last 365 days (21814)
2026 (14129)
2025 (21853)
2024 (25745)
2023 (29865)
2022 (38133)
2021 (41060)
2020 (36844)
2019 (26148)
2018 (19688)
2017 (21460)
2016 (20465)
2015 (26774)
2014 (23508)
2013 (19555)
2012 (21479)
2011 (21700)
2010 (21502)
Location
Africa (280)
Alabama (85)
Alaska (2)
Arizona (328)
Arkansas (13)
Asia (24883)
Australia (3037)
California (12725)
Canada (3258)
China (1142)
Colorado (500)
Connecticut (467)
Delaware (322)
Europe (40958)
Florida (1904)
Georgia (388)
Hawaii (3)
Idaho (46)
Illinois (756)
India (68)
Indiana (378)
Iowa (16)
Japan (466)
Kansas (106)
Kentucky (30)
Louisiana (30)
Maine (27)
Maryland (1300)
Massachusetts (8620)
Michigan (310)
Minnesota (585)
Mississippi (4)
Missouri (85)
Montana (20)
Nebraska (12)
Nevada (116)
New Hampshire (64)
New Jersey (3034)
New Mexico (15)
New York (3202)
North Carolina (1462)
North Dakota (4)
Northern California (6444)
Ohio (289)
Oklahoma (19)
Oregon (24)
Pennsylvania (2363)
Puerto Rico (24)
Rhode Island (32)
South America (482)
South Carolina (76)
South Dakota (1)
Southern California (5223)
Tennessee (123)
Texas (1997)
United States (42177)
Utah (373)
Vermont (1)
Virginia (170)
Washington D.C. (41)
Washington State (991)
West Virginia (1)
Wisconsin (84)
Wyoming (1)
530,405 Results for "ipsen biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.
August 20, 2026
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions
Ipsen makes up to $1.75B blood cancer bet with Kartos buyout
The star of Ipsen’s acquisition is an MDM2 blocker being proposed as an add-on therapy to ruxolitinib for myelofibrosis. The drug could be available to patients “as early as 2028,” according to Ipsen CEO David Loew.
June 29, 2026
·
2 min read
·
Tristan Manalac
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
Ipsen is penning its second acquisition of the week, this time securing Memo Therapeutics and its midstage monoclonal antibody in a deal that could approach $800 million.
July 1, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
August 21, 2026
·
6 min read
Press Releases
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline
July 22, 2026
·
7 min read
Press Releases
Ipsen - Half year statement - 2026 06 30
July 7, 2026
·
5 min read
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated safety risk in patients undergoing treatment.
March 9, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Ipsen nominates Catherine Bradley to its Board of Directors as independent Director
July 29, 2026
·
6 min read
Press Releases
Ipsen provides update on Phase III BOLD trial in biliary atresia
July 24, 2026
·
9 min read
Press Releases
Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
July 30, 2026
·
11 min read
1 of 53,041
Next
